Patents by Inventor Ann C. Horan

Ann C. Horan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110269216
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Application
    Filed: May 2, 2011
    Publication date: November 3, 2011
    Applicant: Schering Corporation
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Patent number: 7947480
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 24, 2011
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Publication number: 20110027865
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel eveminomicin-related compounds based on eveminomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Application
    Filed: September 3, 2010
    Publication date: February 3, 2011
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Patent number: 7790411
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: September 7, 2010
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Publication number: 20090004649
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Application
    Filed: April 25, 2007
    Publication date: January 1, 2009
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Patent number: 7229813
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: June 12, 2007
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Patent number: 7220567
    Abstract: Plasmid genes from Micromonospora carbonacea var. africana ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: May 22, 2007
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Jr., Ann C. Horan
  • Patent number: 6861513
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: March 1, 2005
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Publication number: 20040101832
    Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.
    Type: Application
    Filed: January 11, 2001
    Publication date: May 27, 2004
    Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
  • Patent number: 6569668
    Abstract: Plasmid genes from Micromonospora rosaria pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: May 27, 2003
    Assignee: Schering Corporation
    Inventors: Thomas J. Hosted, Jr., Ann C. Horan
  • Publication number: 20020076788
    Abstract: Plasmid genes from Micromonospora carbonacea var. africana ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.
    Type: Application
    Filed: May 15, 2001
    Publication date: June 20, 2002
    Inventors: Thomas J. Hosted, Ann C. Horan
  • Publication number: 20020015989
    Abstract: Plasmid genes from Micromonospora rosaria pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.
    Type: Application
    Filed: March 29, 2001
    Publication date: February 7, 2002
    Inventors: Thomas J. Hosted, Ann C. Horan
  • Patent number: 6017894
    Abstract: Three novel macrolactam monosaccharides isolated from an antimicrobial complex 510 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. uruguayensis ATCC 53713.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: January 25, 2000
    Assignee: Schering Corporation
    Inventors: Raymond Cooper, Ann C. Horan, Mahesh G. Patel, Imbi Truumees, Raymond F. Yarborough
  • Patent number: 5837691
    Abstract: A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura vulgaris subsp. vulgaris ATCC 53748.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: November 17, 1998
    Assignee: Schering Corporation
    Inventors: Vinod R. Hegde, Ann C. Horan, Mahesh G. Patel, Ingrid-Agneta Gunnarsson
  • Patent number: 5618809
    Abstract: N-alkanoyl derivatives of staurospodne represented by the formula I ##STR1## wherein R.sub.a and R.sub.b are each H or ##STR2## wherein R.sub.1 and R.sub.2 are independently H or --OH or --OCH.sub.3 and R.sub.3 is OH, NHCH.sub.3, NCH COCH.sub.3 or NHCOCH.sub.3 and R.sub.4 is OH or H and, stereochemical isomers thereof with the provisos that (1) when R.sub.a and R.sub.b .dbd.A, and R.sub.1.dbd.H.sub.2 or OH R.sub.3 is not NHCH.sub.3 ; (2) when R.sub.a and R.sub.b.dbd. B, then R.sub.1 .dbd.R.sub.4 .dbd.OH or R.sub.1 .dbd.R.sub.4 .dbd.H; (3) when R.sub.a .dbd.R.sub.b .dbd.H R.sub.1 .dbd.--OCH.sub.3, and (4) when R.sub.a and R.sub.b .dbd.A, and R.sub.1 .dbd.H and R.sub.2 .dbd.OCH.sub.3, then R3 is not and ##STR3## pharmaceutical compositions thereof useful for inhibiting myosin light chain kinase, protein kinase C or tumor cell proliferation as well as producing an antihypertensive effect and an anti-inflammatory effect in warm-blood animals such as man are disclosed.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: April 8, 1997
    Assignee: Schering Corporation
    Inventors: Ellen B. Barrabee, Ann C. Horan, Frank A. Gentile, Mahesh G. Patel
  • Patent number: 5494913
    Abstract: Compounds of the formulas: ##STR1## or pharmaceutically acceptable salts thereof. These compounds are obtainable by cultivation of a pure culture of Actinoplanes sp. SCC2314, ATCC 55600. These compounds are useful as antifungal agents.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: February 27, 1996
    Assignee: Schering Corporation
    Inventors: Min Chu, Mahesh G. Patel, Ann C. Horan, Joseph Terracciano
  • Patent number: 5446207
    Abstract: Compounds of the formula: ##STR1## wherein a is a single bond and b is a double bond; or a is a double bond and b is a single bond; and enantiomers thereof; or a pharmaceutically acceptable salt thereof are described. These compounds can improve lipoprotein profile of dyslipidemic patients and generate an anti-atherogenic lipoprotein profile of normolipidemic individuals. In addition, inhibition of CETP activity may be useful as antifertility agents.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: August 29, 1995
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Shirley A. Pomponi, Vincent P. Gullo, Ann C. Horan, Mahesh G. Patel, Stephen J. Coval
  • Patent number: 5420261
    Abstract: Two novel glycosides of 3'-deoxyaquayamycin isolated from an antimicrobial complex produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces sp. SCC 2136, ATCC 55186 are disclosed.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: May 30, 1995
    Assignee: Schering Corporation
    Inventors: Min Chu, Ann C. Horan, Joseph A. Marquez, Mahesh G. Patel
  • Patent number: 5378626
    Abstract: Novel macrocyclic lactone antibacterials isolated from a culture containing the microorganism S. aerocolongenes sub sp. antibiotica SCC 1886, ATTC 55003 and their use for treating and/or preventing antibacterial infections, especially Chlamydia infections are disclosed.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: January 3, 1995
    Assignee: Schering Corporation
    Inventor: Ann C. Horan
  • Patent number: 5352707
    Abstract: A method for treating airway congestion which comprises administering an effective amount of the compound of formula II which follows ##STR1## or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: October 4, 1994
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Shirley A. Pompni, Vincent P. Gullo, Ann C. Horan, Mahesh G. Patel, Stephen Coval